References

Aburto M, Herráez I, Iturbe D, Jiménez-Romero A Diagnosis of idiopathic pulmonary fibrosis: differential diagnosis. Med Sci (Basel). 2018; 6:(3) https://doi.org/10.3390/medsci6030073

Patient Survey Report 2018. Giving patients a voice. 2019; https://tinyurl.com/ybmmgu3c

Ahmadi NS, Månsson J, Lindblad U, Hildingh C Breathlessness in everyday life from a patient perspective: A qualitative study using diaries. Palliat Support Care. 2014; 12:(3)189-194 https://doi.org/10.1017/S1478951512001095

Aiello M, Bertorelli G, Bocchino M The earlier, the better: impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017; 44:7-15 https://doi.org/10.1016/j.pupt.2017.02.005

Types and causes. 2020; https://tinyurl.com/y8gdajxz

Barley E, Lawson V Using health psychology techniques to manage chronic physical symptoms. Br J Nurs. 2016; 25:(22)1258-1262 https://doi.org/10.12968/bjon.2016.25.22.1258

Barratt SL, Mulholland S, Al Jbour K South West of England's experience of the safety and tolerability pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). Frontiers in Pharmacology. 2018; 9 https://doi.org/10.3389/fphar.2018.01480

Bonella F, Wijsenbeek M, Molina-Molina M European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016; 47:(2)597-606 https://doi.org/10.1183/13993003.01204-2015

The battle for breath—the impact of lung disease in the UK. 2016; https://tinyurl.com/y4efpyzk

What causes IPF?. 2019; https://tinyurl.com/ydersf5e

Collard HR, Tino G, Noble PW, Shreve MA, Michaels M, Carlson B, Schwarz MI Patient experiences with pulmonary fibrosis. Respir Med. 2007; 101:(6)1350-1354 https://doi.org/10.1016/j.rmed.2006.10.002

Costabel U, Bendstrup E, Cottin V Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014; 31:(4)375-391 https://doi.org/10.1007/s12325-014-0112-1

Dickinson CJ, Martin JF Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet. 1987; 2:(8573)1434-1435 https://doi.org/10.1016/s0140-6736(87)91132-9

Duck A, Spencer LG, Bailey S, Leonard C, Ormes J, Caress AL Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs. 2015; 71:(5)1055-1065 https://doi.org/10.1111/jan.12587

Duncan D, Ashby A Managing chronic breathlessness in the community. Br J Community Nurs. 2018; 23:(7)318-321 https://doi.org/10.12968/bjcn.2018.23.7.318

Ehrlich SF, Quesenberry CP, Van Den Eeden SK, Shan J, Ferrara A Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010; 33:(1)55-60 https://doi.org/10.2337/dc09-0880

Ekström M, Gustafson T, Boman K Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study. BMJ Open. 2014; 4:(1) https://doi.org/10.1136/bmjopen-2013-004018

The EU-IPFF Consultation Guide:a guide to living with idiopathic pulmonary fibrosis. 2018; https://tinyurl.com/yb2h83bx

Garcia MV, Luckett T, Johnson M, Hutchinson A, Lal S, Phillips JL The roles of dispositional coping style and social support in helping people with respiratory disease cope with a breathlessness crisis. J Adv Nurs. 2019; 75:(9)1953-1965 https://doi.org/10.1111/jan.14039

Glaspole IN, Watson AL, Allan H Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. Eur Respir J. 2017; 50:(2) https://doi.org/10.1183/13993003.00168-2017

Graney BA, Wamboldt FS, Baird S Looking ahead and behind at supplemental oxygen: A qualitative study of patients with pulmonary fibrosis. Heart Lung. 2017; 46:(5)387-393 https://doi.org/10.1016/j.hrtlng.2017.07.001

Hajari Case A, Johnson P Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2017; 4:(1) https://doi.org/10.1136/bmjresp-2017-000192

Heathcote KL, Cockcroft DW, Fladeland DA, Fenton ME Normal expiratory flow rate and lung volumes in patients with combined emphysema and interstitial lung disease: a case series and literature review. Can Respir J. 2011; 18:(5)e73-e76 https://doi.org/10.1155/2011/354325

Hewson T, McKeever TM, Gibson JE, Navaratnam V, Hubbard RB, Hutchinson JP Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax. 2018; 73:683-685 https://doi.org/10.1136/thoraxjnl-2017-210177

Hu Y, Ma Z, Guo Z Type 1 diabetes mellitus is an independent risk factor for pulmonary fibrosis. Cell Biochem Biophys. 2014; 70:(2)1385-1391 https://doi.org/10.1007/s12013-014-0068-4

Janssen K, Rosielle D, Wang Q, Kim HJ The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study. Respir Res. 2020; 21:(1) https://doi.org/10.1186/s12931-019-1266-9

British National Formulary: Pirfenidone. 2020a; https://bnf.nice.org.uk/drug/pirfenidone.html

British National Formulary: Nintedanib. 2020b; https://bnf.nice.org.uk/drug/nintedanib.html

Kim JS, Podolanczuk AJ, Borker P Obstructive sleep apnea and subclinical interstitial lung disease in the Multi-Ethnic Study of Atherosclerosis (MESA). Ann Am Thorac Soc. 2017; 14:(12)1786-1795 https://doi.org/10.1513/AnnalsATS.201701-091OC

Lancaster LH, Mason WR, Parnell JA Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009; 136:(3)772-778 https://doi.org/10.1378/chest.08-2776

Lindell KO, Kavalieratos D, Gibson KF, Tycon L, Rosenzweig M The palliative care needs of patients with idiopathic pulmonary fibrosis: A qualitative study of patients and family caregivers. Heart Lung. 2017; 46:(1)24-29 https://doi.org/10.1016/j.hrtlng.2016.10.002

Liu T, Ullenbruch M, Young Choi Y Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013; 49:(2)260-268 https://doi.org/10.1165/rcmb.2012-0514OC

Meltzer EB, Noble PW Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008; 3 https://doi.org/10.1186/1750-1172-3-8

Naik PK, Moore BB Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med. 2010; 4:(6)759-771 https://doi.org/10.1586/ers.10.73

Idiopathic pulmonary fibrosis in adults. QS79. 2015; https://tinyurl.com/yczsszcw

Nintedanib for treating idiopathic pulmonary fibrosis. Technology appraisal guidance [TA379]. 2016; https://www.nice.org.uk/guidance/ta379

Idiopathic pulmonary fibrosis in adults: diagnosis and management. CG163. 2017; https://tinyurl.com/ydxttysg

Pirfenidone for treating idiopathic pulmonary fibrosis. Technology appraisal guidance [TA504]. 2018a; https://tinyurl.com/ybv33sdr

Pulmonary rehabilitation improves exercise tolerance in pulmonary fibrosis. 2018; https://doi.org/10.3310/signal-00570

Who should have the pneumococcal vaccine?. 2019; https://tinyurl.com/ybhuoofr

Oh CK, Murray LA, Molfino NA Smoking and idiopathic pulmonary fibrosis. Pulm Med. 2012; 2012:1-13 https://doi.org/10.1155/2012/808260

Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366:(21)1968-1977 https://doi.org/10.1056/NEJMoa1113354

Raghu G, Freudenberger TD, Yang S High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006; 27:(1)136-142 https://doi.org/10.1183/09031936.06.00037005

Raghu G, Remy-Jardin M, Myers JL Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198:(5)e44-e68 https://doi.org/10.1164/rccm.201807-1255ST

Richeldi L, Collard HR, Jones MG Idiopathic pulmonary fibrosis. Lancet. 2017; 389:(10082)1941-1952 https://doi.org/10.1016/S0140-6736(17)30866-8

Sack C, Rague G Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors. Eur Respir J. 2018; 2018 https://doi.org/10.1183/13993003.01699-2018

Sarkar M, Mahesh DM, Madabhavi I Digital clubbing. Lung India. 2012; 29:(4)354-62 https://doi.org/10.4103/0970-2113.102824

Shammas MA Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab Care. 2011; 14:(1)28-34 https://doi.org/10.1097/MCO.0b013e32834121b1

Snell N, Strachan D, Hubbard R, Gibson J, Maher T, Jarrold I P272 Epidemiology of idiopathic pulmonary fibrosis in the UK: findings from the British lung foundation's ‘respiratory health of the nation’ project. Thorax. 2016; 71 https://doi.org/10.1136/thoraxjnl-2016-209333.415

Speakman L, Walthall H Assessment and management of refractory breathlessness in interstitial lung disease. Br J Community Nurs. 2017; 22:(9)434-439 https://doi.org/10.12968/bjcn.2017.22.9.434

Strongman H, Kausar I, Maher TM Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK. Adv Ther. 2018; 35:(5)724-736 https://doi.org/10.1007/s12325-018-0693-1

Subramanian MP, Meyers BF Bilateral versus single lung transplantation: are two lungs better than one?. J Thorac Dis. 2018; 10:(7)4588-4601 https://doi.org/10.21037/jtd.2018.06.56

Tarrant B, Le Maitre C, Romero L Mucoactive agents for adults with acute lung conditions: a systematic review. Heart Lung. 2019; 48:(2)141-147 https://doi.org/10.1016/j.hrtlng.2018.09.010

Taskar VS, Coultas DB Is idiopathic pulmonary fibrosis an environmental disease?. Proc Am Thorac Soc. 2006; 3:(4)293-298 https://doi.org/10.1513/pats.200512-131TK

A national five year plan for lung health. 2018; https://tinyurl.com/y9nv28sf

Tobin RW, Pope CE, Pellegrini CA, Emond MJ, Sillery J, Raghu G Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 158:(6)1804-1808 https://doi.org/10.1164/ajrccm.158.6.9804105

van Manen MJG, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, Wijsenbeek MS Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016; 25:(141)278-286 https://doi.org/10.1183/16000617.0090-2015

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018; 51:(5) https://doi.org/10.1183/13993003.00692-2018

Wolters PJ, Collard HR, Jones KD Pathogenesis of idiopathic pulmonary fibrosis. Annual Review of Pathology: Mechanisms of Disease. 2014; 9:(1)157-179 https://doi.org/10.1146/annurev-pathol-012513-104706

Zaman T, Lee JS Risk factors for the development of idiopathic pulmonary fibrosis: A review. Curr Pulmonol Rep. 2018; 7:(4)118-125 https://doi.org/10.1007/s13665-018-0210-7

Respiratory Care
COVID-19

Idiopathic pulmonary fibrosis: a more common condition than you may think

25 March 2021
Professional
02 March 2021
Volume 30 · Issue 6

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive incurable lung disease that affects a significant amount of people in the UK. Many health professionals have a limited understanding of IPF, which can result in a delayed diagnosis and inadequate care for individuals and their families. This article aims to provide an overview of IPF and help to enhance health professionals' understanding of the disease, thus contributing towards improving the care that IPF sufferers receive. This article provides a definition of IPF and explores its pathophysiology. It discusses the causes and risk factors for developing the condition, examines how IPF is diagnosed and details the treatment options available for IPF patients.

The COVID-19 pandemic has brought to the fore an increased awareness of respiratory conditions. Unheard of until a few months ago, SARS-CoV-2, the cause of COVID-19, has become renowned and has prompted a concerted global response to combating the spread of this novel coronavirus, with unprecedented resources being allocated for research and the development of vaccines in an attempt to curb the pandemic. The long-term ill effects of having had a serious episode of COVID-19 are not yet known, but there are early indications that scarring of the lungs is one of the complications. The irony of scarring of the lungs, known as pulmonary fibrosis (PF), is that it is a poorly recognised and misunderstood respiratory condition with variable access to support and resources. This article is timely as a reminder to nurses of the condition and to help consider the specific care and support that this patient group needs to be offered.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content

Register
Or continue by

Signing in with your registered email address

Idiopathic pulmonary fibrosis
IPF
Respiratory disease
Signs and symptoms
Diagnosis
Treatment
Nurse education